10.05.2023

Antibiotic Iasi, the biggest Romanian-held drug producer, is mulling new export markets, including Nordic ones, where it is trying to already develop its first local partnerships. more

09.16.2023

Romanian state-owned pharmaceutical manufacturer Antibiotice (ATB.RO) has called shareholders for a general meeting on October 30, 2023 to secure approval for the conclusion of a financing contract more

08.14.2023

Antibiotice Iasi (ATB.RO), the most important Romanian producer of generic drugs, recorded sales of RON315.9 million in the first half of 2023, a 27% increase compared with the first half of 2022, more

06.07.2023

Antibiotice Iasi (ATB.RO), Romania’s largest producer of generic drugs, on Wednesday notified the Bucharest Stock Exchange of having received RON4.08 million from the Ministry of European Investment more

05.18.2023

Antibiotice Iasi (ATB.RO), Romania’s most important generic drug manufacturer, on Thursday (May 18) informed the Bucharest Stock Exchange (BVB) that SIF Oltenia (SIF5.RO), its second largest more

05.18.2023

Romania’s most important generic drug manufacturer Antibiotice Iasi (ATB.RO) has received from the Romanian government the approval for the funding of a project for manufacturing, packaging and more

05.12.2023

Romanian pharma producer Antibiotice Iasi ended the first quarter of 203 with RON178 million sales, up around 40%, and RON22 million net profit, almost triple the level of the year-earlier period. more

02.27.2023

Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Monday (Feb 27) that it ended 2022 with a net profit of RON38.5 million in 2022. up 28.6% versus 2021, more

02.02.2023

Romanian pharmaceutical producer Antibiotice wants to invest over RON88 million in 2023 in the Iasi production platform, from own resources and reserves, in line with its budget. more

01.18.2023

Romanian pharmaceutical producer Antibiotice Iasi has budgeted RON580 million revenues for 2023, up 11% year-on-year and RON42 million net profit, 10% higher than in 2022. more

12.13.2022

Enel X Romania, part of Enel X Global Retail, the advanced energy services division of Italy’s Enel Group, will build a photovoltaic (PV) park with a total installed capacity of 2.5 MW for Romanian more

12.09.2022

Romanian pharmaceutical manufacturer Antibiotice Iasi is opening a new plant, in the wake of a EUR20 million investment, with a 50% higher production capacity than the existing unit. more

11.11.2022

Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Friday that it ended the first nine months of 2022 with sales revenue of RON361.7 million, up 47% on the more

10.06.2022

Romanian drug maker Antibiotice Iasi has budgeted RON300 million investments for the following years. more

08.18.2022

Romanian pharmaceutical manufacturer Antibiotice (ATB.RO) Iasi’s total revenue from sales reached RON248.1 million in the first half of 2022, up 54% on the RON161.4 million in the year-ago period, more

08.10.2022

Drug manufacturer Antibiotice Iasi (ATB.RO) wants to build two new factories for sterile products and sterile topical products, a total investment of RON200 million. more

05.13.2022

Antibiotice Iasi (ATB.RO), the biggest Romanian-held drug maker, reported a net profit net of RON8.6 million for the first three months of 2022, up 113.7% from the year-earlier period, in line with more

04.15.2022

Antibiotice (ATB), one of the most important Romanian generic drug producers, celebrates 25 years since its listing on the Bucharest Stock Exchange (BVB). The company’s shares have been trading on more

03.10.2022

Antibiotice Iasi, the biggest local Romanian-held drug maker, targets RON1 billion turnover by 2030, in line with its multi-annual plan, with half of this sum due to be generated by exports. more

01.31.2022

Antibiotice Iasi (ATB.RO), the biggest local Romanian-held drug producer, projects total revenues worth RON448 million in 2022, up 15% on the year and net profit of RON32 million, 6% higher than in more

12.10.2021

Antibiotice Iasi, the biggest local Romanian-held drug maker, aims for exports to weigh 50%-60% in turnover by 2028. more

11.12.2021

Antibiotice Iasi (ATB.RO), the largest Romanian-owned pharmaceutical company, on Friday notified the Bucharest Stock Exchange that regional investment fund SIF Oltenia (SIF5.RO) bought 1.5 million more

11.11.2021

The revenue of pharmaceutical company Antibiotice Iasi stood at RON245 million in January-September, an increase of 21% on the year-ago period, its report to the Bucharest Stock Exchange shows. more

08.27.2021

Antibiotice Iasi (ATB.RO), the largest Romanian-held drug maker, on Friday reported on the Bucharest Stock Exchange that regional investment fund SIF Oltenia (SIF5) bought 18 million of its shares, more

07.26.2021

Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, reported sales of RON161.4 million in the first half of 2021, up 10.2% from the same period in 2020, per calculations by more